# DSIP Half Life and Pharmacokinetics: Minutes in Plasma, Saturable Brain Transport

> DSIP half life is only minutes in animal plasma, with no validated human profile. How the delta sleep-inducing peptide is cleared and how it crosses the blood-brain barrier, cited.

Cleared from the blood in minutes, moved into the brain by a specific saturable carrier, and never characterized in a validated human profile. The kinetics that shape every DSIP study.

## The short version

DSIP half life is the single most practical fact about this peptide: in animals, it disappears from the bloodstream within minutes. An enzyme-immunoassay study in dogs, monkeys, and rats measured plasma half-lives on the order of only a few minutes, the result of fast breakdown by the body's enzymes [10]. (Half-life just means the time for half of a dose to clear; a few minutes is very short.) That single number explains a lot: why studies gave DSIP by injection rather than as a pill, why a swallowed version does not really work, and why so much recent effort goes into building more stable versions. Two things to note honestly: there is no validated human half-life for DSIP at all, and despite clearing so fast, some people report effects lasting much longer, a mismatch the science has not fully explained. This page covers how DSIP is cleared and, just as important, how it gets into the brain in the first place.

## How fast DSIP is cleared

The core pharmacokinetic finding comes from a purpose-built enzyme immunoassay used to measure DSIP's metabolic clearance rate after intravenous dosing in dogs, with comparison across species: the plasma half-life was on the order of only a few minutes, species-dependent, attributed to rapid degradation by aminopeptidases and plasma proteins [10]. The breakdown is specific, not random; in rat brain homogenate, DSIP was degraded with release of its N-terminal tryptophan (about 30% released after 7.5 minutes), with an optimal degradation pH of 7.35, and neither morphine nor REM-sleep deprivation altered the rate [11]. Fast, enzyme-driven, and consistent, the picture is of a molecule the body dismantles quickly and deliberately.

## Crossing the blood-brain barrier

A peptide that vanishes from the blood in minutes still has to reach the brain to affect sleep, and DSIP does so by a real, specific mechanism, the lens this whole site is built around. In the vascularly perfused guinea-pig brain, DSIP crossed the blood-brain barrier through a saturable, high-affinity transport system, competitively inhibited by L-tryptophan, evidence of specific carrier binding sites on the capillary membrane rather than passive diffusion [8]. 'Saturable' means the carrier has a finite capacity: once its transporters are busy, the crossing rate maxes out, the fingerprint of a specific mechanism. A dog study built on this by showing that a three-factor model, plasma level times half-life times lipophilicity, predicted entry into the cerebrospinal fluid, giving a rational target for designing analogs that reach the brain better [9].

## Why the kinetics drive everything else

Put the two facts together, minutes-long clearance and a finite-capacity brain carrier, and DSIP's whole research arc makes sense. The short half-life is why the field keeps returning to more stable analogs and engineered delivery: the phosphorylated form DSIP-P and other analogs are reported as more stable or potent [17], and a 2024 fusion peptide built specifically to cross the blood-brain barrier (DSIP-CBBBP) reduced wakefulness by about 31% in a chemically induced insomnia mouse model, outperforming native DSIP [6]. The broader principle, that peptides cross the barrier in both directions through dynamic, saturable transporters that themselves change with development and physiology, is the frame a 2015 review uses to explain how peptide drugs might be routed to the brain at all [14]. The honest gap remains the human one: there is no validated human pharmacokinetic profile for DSIP, so the animal half-life is the best available number, not a confirmed human value [3].

---

An evidence-appraisal digest of the delta sleep-inducing peptide record, read like an instrument panel — the 1977 delta-wave finding and the few small human results logged where the studies confirm them, and the dials that never gave a reading (no receptor, no modern trial, no validated human half-life) left openly blank; no clinic behind the panel and nothing here dosed, supplied, prescribed, or sold.